Cargando…

Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization

ABSTRACT: Target therapies based on BRAF and MEK inhibitors (MAPKi) have changed the therapeutic landscape for metastatic melanoma patients bearing mutations in the BRAF kinase. However, the emergence of drug resistance imposes the necessity to conceive novel therapeutic strategies capable to achiev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fattore, Luigi, Malpicci, Debora, Milite, Ciro, Castellano, Sabrina, Sbardella, Gianluca, Botti, Gerardo, Ascierto, Paolo A., Mancini, Rita, Ciliberto, Gennaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493390/ https://www.ncbi.nlm.nih.gov/pubmed/32933538 http://dx.doi.org/10.1186/s12964-020-00633-7

Ejemplares similares

MicroRNAs in melanoma development and resistance to target therapy
por: Fattore, Luigi, et al.
Publicado: (2017)

ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
por: Fattore, Luigi, et al.
Publicado: (2015)

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin
por: Ruggiero, Ciro Francesco, et al.
Publicado: (2019)

Lysine methyltransferase inhibitors: where we are now
por: Feoli, Alessandra, et al.
Publicado: (2021)

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
por: Fattore, Luigi, et al.
Publicado: (2018)

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
por: Fattore, Luigi, et al.
Publicado: (2015)

In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2020)

NADPH Oxidases: From Molecular Mechanisms to Current Inhibitors
por: Cipriano, Alessandra, et al.
Publicado: (2023)

Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma
por: Ruggiero, Ciro Francesco, et al.
Publicado: (2022)

The emerging role of lysine methyltransferase SETD8 in human diseases
por: Milite, Ciro, et al.
Publicado: (2016)

Age-dependent attenuation of spatial memory deficits by the histone acetyltransferase p300/CBP-associated factor (PCAF) in 3xTG Alzheimer's disease mice
por: Creighton, Samantha D., et al.
Publicado: (2022)

Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma
por: Fattore, Luigi, et al.
Publicado: (2019)

Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance
por: Fattore, Luigi, et al.
Publicado: (2022)

Tumor biobanks in translational medicine
por: Botti, Gerardo, et al.
Publicado: (2012)

Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma
por: Fattore, Luigi, et al.
Publicado: (2020)

Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
por: Pisanu, Maria Elena, et al.
Publicado: (2018)

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021)

Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer
por: Noto, Alessia, et al.
Publicado: (2013)

Discovery of Benzo[d]imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
por: Cipriano, Alessandra, et al.
Publicado: (2022)

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
por: Trojaniello, Claudia, et al.
Publicado: (2023)

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
por: Loria, Rossella, et al.
Publicado: (2022)

Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction–Reconstruction and Fragment-Growing Approach
por: Iannelli, Giulia, et al.
Publicado: (2022)

Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition
por: Fattore, Luigi, et al.
Publicado: (2014)

Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
por: Fattore, Luigi, et al.
Publicado: (2013)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
por: Bifulco, Carlo, et al.
Publicado: (2014)

BRAF-mutant hematopoietic malignancies
por: Abdel-Wahab, Omar, et al.
Publicado: (2014)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
por: Colombino, Maria, et al.
Publicado: (2013)

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
por: Ascierto, Paolo A, et al.
Publicado: (2013)

Depolarization Controls TRAIL-Sensitization and Tumor-Selective Killing of Cancer Cells: Crosstalk with ROS
por: Suzuki-Karasaki, Yoshihiro, et al.
Publicado: (2014)

Immunoscore: a new possible approach for melanoma classification
por: Capone, Mariaelena, et al.
Publicado: (2014)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor
por: Feoli, Alessandra, et al.
Publicado: (2023)

Targeting mutant BRAF in colorectal cancer
por: Carroll, David, et al.
Publicado: (2013)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

The Regulation of ROS- and BECN1-Mediated Autophagy by Human Telomerase Reverse Transcriptase in Glioblastoma
por: Ding, Xuelu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3r4kouc7do3fi70l4mbftuolcp